Ignite Creation Date:
2025-12-24 @ 10:07 PM
Ignite Modification Date:
2026-03-03 @ 6:05 PM
Study NCT ID:
NCT03177135
Status:
UNKNOWN
Last Update Posted:
2017-06-06
First Post:
2017-05-28
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
PROOF OF AMNIOSENSE BLUE IN HOME USAGE AND HOSPITAL
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}}, 'protocolSection': {'designModule': {'phases': ['NA'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'DIAGNOSTIC', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 200}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'NOT_YET_RECRUITING', 'startDateStruct': {'date': '2017-07-01', 'type': 'ESTIMATED'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-05', 'completionDateStruct': {'date': '2018-01-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2017-06-01', 'studyFirstSubmitDate': '2017-05-28', 'studyFirstSubmitQcDate': '2017-06-01', 'lastUpdatePostDateStruct': {'date': '2017-06-06', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2017-06-06', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2017-12-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'AmnioSense performance', 'timeFrame': '10 minutes', 'description': 'The primary efficacy endpoints are: presence or absence of a blue or green stain on a yellow background as confirmed by the study team yielded by the AMNIOSENSE Blue, compared to the "hospital standard procedure" - final clinical diagnosis (positive/negative) to assess the agreement between the subject/study team reading and final clinical diagnosis, in both study group 1 (hospital usage and 2 home usage).'}]}, 'oversightModule': {'oversightHasDmc': False, 'isFdaRegulatedDrug': False, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['Amniotic Problems']}, 'descriptionModule': {'briefSummary': 'This is a Prospective study to demonstrate that the AMNIOSENSE Blue pad can reliably rule in or rule out amniotic fluid leak as a cause of vaginal wetness in pregnancy, thus, can be adopted by hospitals as an amniotic fluid leak detection tool, and can be recommended by care providers for use in a home usage setting.\n\nStudy Group 1: Women attending the triage / delivery room with unidentified will be provided with an AMNIOSENSE Blue pad to use in hospital until they notice any wetness prior to a clinical assessment as per hospital standard procedure.\n\nThe clinician performing clinical diagnosis tests for amniotic fluid leak detection, according to the hospital standard procedure will be at all times blinded to the results of the AMNIOSENSE Blue pad.\n\nStudy Group 2: Women attending the obstetrical antenatal clinic for a routine antenatal visit \\> 36+0, and has not been referred for further assessment in triage/delivery unit by the physician will recruited to this study group (Study Group 2). Before leaving the antenatal clinic, they will be given one AMNIOSENSE Blue pad to use at home when vaginal wetness is experienced or in any case when they suspect that they have amniotic fluid leakage. The participant will be instructed to arrive at the hospital within 2 hours of applying the AMNIOSENSE Blue pad, regardless of the test results (positive or negative), to have a clinical diagnosis by the attending physician.', 'detailedDescription': "This is a Prospective study to demonstrate that the AMNIOSENSE Blue pad can reliably rule in or rule out amniotic fluid leak as a cause of vaginal wetness in pregnancy, thus, can be adopted by hospitals as an amniotic fluid leak detection tool, and can be recommended by care providers for use in a home usage setting.\n\nStudy Group 1: Women attending the triage / delivery room with unidentified wetness will be provided with an AMNIOSENSE Blue pad to use in hospital until they notice any wetness but for no longer than 2 hours prior to a clinical assessment as per hospital standard procedure.\n\nThe clinician performing clinical diagnosis tests (clinical assessment) for amniotic fluid leak detection, according to the hospital standard procedure will be at all times blinded to the results of the AMNIOSENSE Blue pad.\n\nClinical diagnosis of ROM and subsequent management of care will be determined as per clinicians' judgment using the standard hospital procedures of ferning and/or positive Nitrazine testing and/or sterile speculum examination.\n\nThe research team or attending nurse (non-bias to the subject's result record) will read the results of the AMNIOSENSE Blue pad, record the results in the data collection forms, and place the AMNIOSENSE Blue pad in a sealed envelope labeled with the study ID. These results will not be communicated to the attending clinicians who will remain blinded.\n\nIn each case, the subject will also be required to read and record any occurrence of color change of the AMNIOSENSE Blue 10 minutes after removing the test on the designated form.\n\nStudy Group 2: Women attending the obstetrical antenatal clinic for a routine antenatal visit \\> 36+0, and has not been referred for further assessment in triage/delivery unit by the physician will recruited to this study group (Study Group 2). Before leaving the antenatal clinic, they will be given one AMNIOSENSE Blue pad to use at home when vaginal wetness is experienced or in any case when they suspect that they have amniotic fluid leakage.\n\nThe participants will be provided with instructions for use and also instructed to read the Instructions For Use (IFU) prior to applying the AMNIOSENSE Blue pad. They will be instructed to only apply the AMNIOSENSE Blue pad when they are planning to attend the triage/delivery unit for assessment of wetness/leaking. The participant will be instructed to arrive at the hospital within 2 hours of applying the AMNIOSENSE Blue pad, regardless of the test results (positive or negative), to have a clinical diagnosis by the attending physician.\n\nUpon arrival to the triage/delivery unit, the participant and the attending nurse or research team member (non-bias to the subject's result record) will retrieve the AMNIOSENSE Blue pad and record the results in the designated data collection forms and place the AMNIOSENSE Blue pad in a sealed envelope labeled with the study ID. These results will not be communicated to the attending clinicians who will remain blinded.\n\nIn each case, the subject will also be required to read and record any occurrence of color change of the AMNIOSENSE Blue 10 minutes after removing the test on the designated form.\n\nWhile in the hospital, participants will be managed according to standard hospital procedure at the discretion of the clinician and have clinical diagnostic tests (clinical assessment) for amniotic fluid leak detection, according to the hospital standard procedure. The clinician will be blinded to the results of the AMNIOSENSE Blue during the study, and as such subject treatment will be based only on the standard hospital diagnostic methods."}, 'eligibilityModule': {'sex': 'FEMALE', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\nGroup 1:\n\n* Age 18 and above.\n* Subject minimum 26+0 weeks of pregnancy.\n* Subject presents with feeling of vaginal wetness.\n\nGroup 2:\n\n* Age 18 and above\n* Subject minimum 36+0 weeks of pregnancy\n* Subject presents with a feeling of vaginal wetness, and has applied the AMNIOSENSE Blue pad prior to arriving at the triage/delivery unit\n\nExclusion Criteria:\n\n* Subject is unable or unwilling to comply with study procedures\n* Subject with active vaginal bleeding present at the time of admission to triage\n* Evidence of a non-reassuring fetal status at the time of assessment in triage (abnormal fetal heart tracing)\n* Subject has reported to have had sexual intercourse within the last 12 hours'}, 'identificationModule': {'nctId': 'NCT03177135', 'briefTitle': 'PROOF OF AMNIOSENSE BLUE IN HOME USAGE AND HOSPITAL', 'organization': {'class': 'OTHER', 'fullName': 'Common Sense'}, 'officialTitle': 'PROOF OF AMNIOSENSE BLUE IN HOME USAGE AND AS A HOSPITAL STANDARD OF CARE FOR AMNIOTIC FLUID LEAK DETECTION', 'orgStudyIdInfo': {'id': 'F-7-32.3-1'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'AmnioSense diagnostic pantyliner', 'description': 'AmnioSense diagnostic pantyliner of amniotic fluid compared with standard clinical diagnosis methods', 'interventionNames': ['Device: AmnioSense']}], 'interventions': [{'name': 'AmnioSense', 'type': 'DEVICE', 'description': 'A diagnostic pantyliner for detection of amniotic fluid leaks compared with standard clinical diagnosis.', 'armGroupLabels': ['AmnioSense diagnostic pantyliner']}]}, 'contactsLocationsModule': {'centralContacts': [{'name': 'Amanda Amanda, MD', 'role': 'CONTACT', 'email': 'ablack@ottawahospital.on.ca', 'phone': '613-738-8400', 'phoneExt': '81739'}, {'name': 'Natalie Rybak, BSc', 'role': 'CONTACT', 'email': 'nrybak@ohri.ca', 'phone': '613-737-8899', 'phoneExt': '75235'}], 'overallOfficials': [{'name': 'Amanda Amanda, MD', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Ottawa Hospital Research Institute'}]}, 'ipdSharingStatementModule': {'ipdSharing': 'NO'}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Common Sense', 'class': 'OTHER'}, 'responsibleParty': {'type': 'SPONSOR'}}}}